$6.38
6.51% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US42328V5049
Symbol
HSDT

Helius Medical Technologies Inc Class A Stock price

$6.38
-1.92 23.13% 1M
-389.62 98.39% 6M
-496.35 98.73% YTD
-539.24 98.83% 1Y
-20,618.62 99.97% 3Y
-555,968.62 100.00% 5Y
-4,495,306.12 100.00% 10Y
-14,189,431.12 100.00% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.39 6.51%

Key metrics

Basic
Market capitalization
$6.9m
Enterprise Value
$5.8m
Net debt
positive
Cash
$1.1m
Shares outstanding
10.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.0 | 18.0
EV/Sales
13.4 | 15.1
EV/FCF
negative
P/B
5.4
Financial Health
Equity Ratio
29.9%
Return on Equity
-1,108.8%
ROCE
-979.6%
ROIC
-1,367.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$430.0k | $381.5k
EBITDA
$-14.5m | -
EBIT
$-14.5m | $-14.6m
Net Income
$-13.1m | $-2.6m
Free Cash Flow
$-11.6m
Growth (TTM | estimate)
Revenue
4.9% | -26.6%
EBITDA
-65.1% | -
EBIT
-64.5% | -5.0%
Net Income
-80.9% | 77.9%
Free Cash Flow
-819.1%
Margin (TTM | estimate)
Gross
-33.6%
EBITDA
-3,336.6% | -
EBIT
-3,340.6%
Net
-3,010.1% | -677.8%
Free Cash Flow
-2,667.3%
More
EPS
$-1,296.0
FCF per Share
$-1,157.6
Short interest
5.9%
Employees
21
Rev per Employee
$20.0k
Show more

Is Helius Medical Technologies Inc Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Helius Medical Technologies Inc Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Helius Medical Technologies Inc Class A forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Helius Medical Technologies Inc Class A forecast:

Hold
50%
Sell
50%

Financial data from Helius Medical Technologies Inc Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.43 0.43
5% 5%
100%
- Direct Costs 0.58 0.58
45% 45%
135%
-0.15 -0.15
1,600% 1,600%
-35%
- Selling and Administrative Expenses 10 10
62% 62%
2,437%
- Research and Development Expense 3.82 3.82
77% 77%
888%
-14 -14
65% 65%
-3,367%
- Depreciation and Amortization 0.02 0.02
60% 60%
5%
EBIT (Operating Income) EBIT -14 -14
64% 64%
-3,372%
Net Profit -13 -13
81% 81%
-3,037%

In millions USD.

Don't miss a Thing! We will send you all news about Helius Medical Technologies Inc Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Helius Medical Technologies Inc Class A Stock News

Neutral
GlobeNewsWire
about one month ago
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication fo...
Neutral
GlobeNewsWire
about 2 months ago
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the “Panel”) indicatin...
Neutral
GlobeNewsWire
about 2 months ago
NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on June 30, 202...
More Helius Medical Technologies Inc Class A News

Company Profile

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Head office United States
CEO Dane Andreeff
Employees 21
Founded 2014
Website heliusmedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today